Most patients with complex malignancies show a high level of toxicity and limited long-
lasting responses to current conventional therapies. In contrast, the immune system has the …

It has been intensively reported that the immunosuppressive tumor microenvironment (TME)
results in tumor resistance to immunotherapy, especially immune checkpoint blockade and …

Oncolytic virus (OV) therapy is potentially a game-changing cancer treatment that has
garnered significant interest due to its versatility and multi-modal approaches towards tumor …

Oncolytic virus (OV) therapy is a promising cancer treatment strategy, which selectively
replicates in and destroys tumor cells rather than normal cells, thereby effectively releasing …

In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently
seen as a potential therapeutic option for patients with cancer who do not respond or fail to …

Oncolytic viruses have found a good place in the treatment of cancer. Administering
oncolytic viruses directly or by applying genetic changes can be effective in cancer treatment …

Immuno-oncology (IO) has been an active area of oncology research. Following US FDA
approval of the first immune checkpoint inhibitor (ICI), ipilimumab (human IgG1 k anti-CTLA …

Immunotherapy has been extensively explored in recent years with encouraging results in
selected types of cancer. Such success aroused interest in the expansion of such …

Immunotherapies using immune checkpoint inhibitors (ICIs) and chimeric antigen receptor
(CAR) T-cell therapy have achieved successful results against several types of human …

Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with
cancers resistant to traditional therapies. Natural or genetically modified OVs are …